Selected references: Myeloid cell manufacturing with Miltenyi Biotec solutions

Logo

Selected references: Myeloid cell manufacturing with Miltenyi Biotec solutions

Dendritic cells (DCs) and macrophages play a crucial role in next-generation cell therapies. The CliniMACS Prodigy® and CliniMACS® Plus Instruments support automated and standardized manufacturing workflows tailored for clinical use.

These clinical publications highlight how the cell manufacturing instruments, along with gentleMACS® Dissociators and MACS® GMP Products, are used in clinical settings to enable reliable and scalable cell manufacturing.

Choose your topic of interest

Content

  • Manufacturing of macrophages
  • Blood-derived DC manufacturing
  • Monocyte-derived DC manufacturing
  • Tolerogenic DC manufacturing
  • Progenitor-derived DC manufacturing
  • Validation of DC vaccine manufacturing
  • gentleMACS Dissociators and MACS GMP Products
  • Clinical trials (summary table)

Manufacturing of macrophages with CliniMACS Instruments

  • Autologous macrophage therapy for liver cirrhosis: A phase 2 open-label randomized controlled trial.
    Brennan, P. N. et al. (2025) Nat. Med. 31: 979–987. | Read article

  • Study protocol: A multicentre, open-label, parallel-group, phase 2, randomised controlled trial of autologous macrophage therapy for liver cirrhosis (MATCH).
    Brennan, P. N. et al. (2021) BMJ Open 11: e053190. | Read article

  • Development, functional characterization and validation of methodology for GMP-compliant manufacture of phagocytic macrophages: A novel cellular therapeutic for liver cirrhosis.
    Fraser, A.R. et al. (2017) Cytotherapy 17: 30592–30593. | Read article

Blood-derived DC manufacturing with CliniMACS Instruments

  • Adjuvant dendritic cell therapy in stage IIIB/C melanoma: The MIND-DC randomized phase III trial.
    Bol, K.F. et al. (2024) Nat. Commun. 15: 1632. | Read article

  • Intratumoral administration of the immunologic adjuvant AS01B in combination with autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma.
    Tijtgat, J. et al. (2024) J. Immunother. Cancer 12: e008148. | Read article

  • A randomized phase II clinical trial of stereotactic body radiation therapy (SBRT) and systemic pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells in solid tumors.
    Vounckx, M. et al. (2024) Cancer Immunol. Immunother. 73: 167. | Read article

  • Fully closed and automated enrichment of primary blood dendritic cells for cancer immunotherapy.
    Schreibelt, G. et al. (2024) Methods Cell Biol. 183: 33–50. | Read article

  • Intratumoral administration of CD1c (BDCA-1)+ and CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: A phase I clinical trial.
    Schwarze, J.K. et al. (2022) J. Immunother. Cancer 10: e005141. | Read article

  • Immunological responses to adjuvant vaccination with combined CD1c+ myeloid and plasmacytoid dendritic cells in stage III melanoma patients. Oncoimmunology.
    Bloemendal, M. et al. (2021) Oncoimmunology 11: 2015113. | Read article

  • Intratumoral combinatorial administration of CD1c (BDCA-1)+ myeloid dendritic cells plus ipilimumab and avelumab in combination with intravenous low-dose nivolumab in patients with advanced solid tumors: A phase IB clinical trial.
    Schwarze, J.K. et al. (2020) Vaccines 8: 670. | Read article

  • Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration resistant prostate cancer.
    Westdorp, H. et al. (2019) J. Immunother. Cancer 7: 302. | Read article

  • Preclinical exploration of combining plasmacytoid and myeloid dendritic cell vaccination with BRAF inhibition.
    Tel, J., De Haas, N. et al. (2016) J. Transl. Med. 14: 88. | Read article

  • Expansion of BDCA1+CD14+ myeloid cell population in melanoma patients may attenuate the efficacy of dendritic cell vaccines.
    Bakdash, G. et al. (2016) Cancer Res. 15: 4332–4346. | Read article

  • Effective clinical responses in metastatic melanoma patients after vaccination with primary myeloid dendritic cells.
    Schreibelt, G. et al. (2015) Clin. Cancer Res. 9: 2155–2166. | Read article

  • A phase I clinical trial of CD1c (BDCA-1)+ dendritic cells pulsed with HLA-A*0201 peptides for immunotherapy of metastatic hormone refractory prostate cancer.
    Prue, R. L. et al. (2015) J. Immunother. 38: 71–6. | Read article

  • Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients.
    Tel, J. et al. (2013) Cancer Res. 3: 1063–1075. | Read article

Monocyte-derived DC manufacturing with CliniMACS Instruments

Dendritic cell vaccination for solid tumors

  • WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: Type 1 T-lymphocyte responses are associated with clinical outcome.
    Berneman, Z.N. et al. (2025) J. Hematol. Oncol. 18: 9. | Read article

  • Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum.
    Ingels, J. et al. (2024) Cell Rep. Med. 5: 101516. | Read article

  • Dendritic cells loaded with allogeneic tumour cell lysate plus best supportive care versus best supportive care alone in patients with pleural mesothelioma as maintenance therapy after chemotherapy (DENIM): A multicentre, open-label, randomised, phase 2/3 study.
    Aerts, J.G. et al. (2024) Lancet Oncol. 25: 865–878. | Read article

  • Dendritic cell-based immunotherapy in patients with resected pancreatic cancer.
    van 't Land, F.R. et al. (2024) J. Clin. Oncol. 42: 3083–3093. | Read article

  • Adjuvant dendritic cell-based immunotherapy after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with malignant peritoneal mesothelioma: A phase II clinical trial.
    Dietz, M.V. et al. (2023) J. Immunother. Cancer 11: e007070. | Read article

  • Autologous dendritic cells pulsed with allogeneic tumour cell lysate induce tumour-reactive T-cell responses in patients with pancreatic cancer: A phase I study.
    Lau, S.P. et al. (2022) Eur. J. Cancer 169: 20–31. | Read article

  • A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP‑DC) or with tumor lysate (OC‑DC) in patients with advanced high‑grade ovarian serous carcinoma.
    Sarivalasis, A. et al. (2019) J. Transl. Med. 17: 391. | Read article

  • Autologous dendritic cells pulsed with allogeneic tumor cell lysate in mesothelioma: From mouse to human.
    Aerts, J.G. et al. (2018) Clin. Cancer Res. 24: 766–776. | Read article

  • A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients.
    Inoges, S., Tejada, S. et al. (2017) J. Transl. Med. 15: 104. | Read article

  • Dendritic cell vaccination in glioblastoma after fluorescence-guided resection.
    Valle, R.D. et al. (2012) World J. Clin. Oncol. 3: 142–149. | Read article

  • An optimized method for manufacturing a clinical scale dendritic cell-based vaccine for the treatment of glioblastoma.
    Nava, S. et al. (2012) PLoS One 12: e52301. | Read article

  • Peptide-pulsed dendritic cell vaccination targeting interleukin-13 receptor a 2 chain in recurrent malignant glioma patients with HLA-A*24/A*02 allele.
    Iwami, K. et al. (2012) Cytotherapy 14: 733–742. | Read article

  • Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients.
    Alfaro, C. et al. (2011) J. Immunol. 187: 6130–42. | Read article

  • PGE2 transiently enhances DC expression of CCR7 but inhibits the ability of DCs to produce CCL10 and attract naive T cells.
    Muthuswamy, R. et al. (2010) Blood 116: 1454–9. | Read article

  • Generation of a dendritic cell-based vaccine in chronic lymphocytic leukaemia using CliniMACS platform for large-scale production.
    Adamson L. et al. (2009) Scand. J. Immunol. 69: 529–36. | Read article

  • Clinical and immunological effect of intranodal autologous tumor lysate-DC vaccine with Aldesleukin (IL-2) and IFN-a 2a therapy in metastatic renal cell carcinoma patients.
    Schwaab, T. et al. (2009) Clin. Cancer Res. 15: 4986–92. | Read article

  • Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells.
    Babatz, J. et al. (2006) Cancer Immunol. Immunother. 55: 268–76. | Read article

  • Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide.
    Höltl, L. et al. (2005) Cancer Immunol. Immunother. 54: 663–70. | Read article

  • Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas.
    Mazzolini, G. et al. (2005) J. Clin. Oncol. 23: 999–1010. | Read article

  • Large-scale immunomagnetic selection of CD14+ monocytes to generate dendritic cells for cancer immunotherapy: A phase I study.
    Babatz, J. et al. (2003) J. Hematother. Stem Cell Res. 12: 515–23. | Read article

Dendritic cell vaccination for leukemia

  • Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia.
    Anguille, S. et al. (2017) Blood 130: 1713–1721. | Read article

  • Vaccination with dendritic cells loaded with tumor apoptotic bodies (Apo-DC) in patients with chronic lymphocytic leukemia: Effects of various adjuvants and definition of immune response criteria.
    Palma, M. et al. (2011) Cancer Immunol. Immunother. 61: 865–879. | Read article

  • Induction of complete and molecular remissions in acute myeloid leukemia by Wilms’ tumor 1 antigen-targeted dendritic cell vaccination.
    Van Tendeloo, V. et al. (2010) Proc. Natl. Acad. Sci. 107: 13824–9. | Read article

  • Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial.
    Van Driessche, A. et al. (2009) Cytotherapy 11: 653–68. | Read article

  • Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: A pilot study.
    Di Nicola, M. et al. (2009) Blood 113: 18–27. | Read article

  • Development of a dendritic cell based vaccine for chronic lymphocytic leukemia.
    Palma, M. et al. (2008) Cancer Immunol. Immunother. 57: 1705–10. | Read article

  • Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides.
    Curti, A. et al. (2007) Br. J. Haematol. 139: 415–24. | Read article

  • Generation of dendritic cells from positively selected CD14+ monocytes for antitumor immunotherapy.
    Curti, A. et al. (2004) Leuk. Lymphoma 45: 1419–28. | Read article

  • Mature myeloid dendritic cells for clinical use prepared from CD14+ cells isolated by immunomagnetic adsorption.
    Padley, D.J. et al. (2001) J. Hematother. Stem Cell Res. 10: 427–9. | Read article

Dendritic cell vaccination for infectious diseases

  • Clinical testing of a dendritic cell targeted therapeutic vaccine in patients with chronic hepatitis C virus infection.
    Zabaleta, A. et al. (2015) Mol. Ther. Methods Clin. Dev. 2: 15006. | Read article

  • Induction of cytomegalovirus-specific T cell responses in healthy volunteers and allogeneic stem cell recipients using vaccination with messenger RNA-transfected dendritic cells.
    Van Craenenbroeck, A. H. et al. (2015) Transplantation 99: 120–127. | Read article

Tolerogenic DC manufacturing with CliniMACS Instruments

  • Tolerogenic dendritic cells pulsed with islet antigen induce long-term reduction in T-cell autoreactivity in type 1 diabetes patients.
    Nikolic, T. et al. (2022) Front. Immunol. 13: 1054968. | Read article

  • Safety and feasibility of intradermal injection with tolerogenic dendritic cells pulsed with proinsulin peptide-for type 1 diabetes.
    Nikolic, T. et al. (2020) Lancet Diabetes Endocrinol. 8: 470–472. | Read article

  • Autologous tolerogenic dendritic cells for rheumatoid and inflammatory arthritis.
    Bell, G.M. et al. (2017) Ann. Rheum. Dis. 76: 227–234. | Read article

Progenitor-derived DC manufacturing with CliniMACS Instruments

  • Development of a GMP production protocol for a cord blood-derived dendritic cell-based vaccine to prevent relapses after hematopoietic cell transplantation in children with AML.
    De Haar, C. et al. (2017) Biol. Blood Marrow Transplant. 23: 161 | Read article

  • Generation of a cord blood-derived Wilms Tumor 1 dendritic cell vaccine for AML patients treated with allogeneic cord blood transplantation.
    De Haar, C. and Plantinga, M. (2015) OncoImmunology 4: 11, e1023973. | Read article

Validation of DC vaccine manufacturing

  • Fully closed and automated enrichment of primary blood dendritic cells for cancer immunotherapy.
    Schreibelt, G. et al. (2024) Methods Cell Biol. 183: 33–50. | Read article

  • Automated closed-system manufacturing of human monocyte-derived dendritic cells for cancer immunotherapy.
    Erdmann, M. et al. (2018) J. Immunol. Methods 463: 89–96. | Read article

  • Generation of DC-based vaccine for therapy of B-CLL patients. Comparison of two methods for enriching monocytic precursors.
    Kokhaei, P. et al. (2006) Cytotherapy 8: 318–26. | Read article

  • Isolation and generation of clinical-grade dendritic cells using the CliniMACS system.
    Campbell, J. D. et al. (2005) Methods Mol. Med. 109: 55–70. | Read article

  • Generation of clinical-grade monocyte derived dendritic cells using the CliniMACS system.
    Putz, T. et al. (2005) Methods Mol. Med. 109: 71–82. | Read article

  • Clinical-grade manufacturing of DC from CD14+ precursors: experience from phase I clinical trials in CML and malignant melanoma.
    Dietz, A.B. et al. (2004) Cytotherapy 6: 563–70. | Read article

  • Efficacy of dendritic cell generation for clinical use: recovery and purity of monocytes and mature dendritic cells after immunomagnetic sorting or adherence selection of CD14+ starting populations.
    Meyer-Wentrup, F. and Burchdach, S. J. (2003) Hematother. Stem Cell Res. 12: 289–99. | Read article

  • Clinical-scale generation of dendritic cells in a closed system.
    Sorg, R. et al. (2003) J. Immunother. 26: 374–83. | Read article

  • Generation of dendritic cells from CD14+ monocytes positively selected by immunomagnetic adsorption for multiple myeloma patients enrolled in a clinical trial of anti-idiotype vaccination.
    Motta, M.R. et al. (2003) Br. J. Haematol. 121: 240–50. | Read article

  • Monocyte enrichment from leukapharesis products for the generation of DCs by plastic adherence, or by positive or negative selection.
    Felzmann, T. et al. (2003) Cytotherapy 5: 391–398. | Read article

  • Optimizing preparation of normal dendritic cells and bcr-abl+ mature dendritic cells derived from immunomagnetically purified CD14+ cells.
    Dietz, A.B. et al. (2000) J. Hematother. Stem Cell Res. 9: 95–101. | Read article

MACS GMP Media, Peptivator® Peptide Pools, Cytokines, Cell Differentiation Bags and gentleMACS Dissociators for cell processing

  • Autologous macrophage therapy for liver cirrhosis: A phase 2 open-label randomized controlled trial.
    Brennan, P. N. et al. (2025) Nat. Med. 31: 979–987. | Read article

  • Dendritic cells loaded with allogeneic tumour cell lysate plus best supportive care versus best supportive care alone in patients with pleural mesothelioma as maintenance therapy after chemotherapy (DENIM): A multicentre, open-label, randomised, phase 2/3 study.
    Aerts, J.G. et al. (2024) Lancet Oncol. 25: 865–878. | Read article

  • Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum.
    Ingels, J. et al. (2024) Cell Rep. Med. 5: 101516. | Read article

  • Adjuvant dendritic cell therapy in stage IIIB/C melanoma: The MIND-DC randomized phase III trial.
    Bol, K.F. et al. (2024) Nat. Commun. 15: 1632. | Read article

  • Dendritic cell-based immunotherapy in patients with resected pancreatic cancer.
    van 't Land, F.R. et al. (2024) J. Clin. Oncol. 42: 3083–3093. | Read article

  • Adjuvant dendritic cell-based immunotherapy after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with malignant peritoneal mesothelioma: A phase II clinical trial.
    Dietz, M.V. et al. (2023) J. Immunother. Cancer 11: e007070. | Read article

  • Autologous dendritic cells pulsed with allogeneic tumour cell lysate induce tumour-reactive T-cell responses in patients with pancreatic cancer: A phase I study.
    Lau, S.P. et al. (2022) Eur. J. Cancer 169: 20–31. | Read article

  • Tolerogenic dendritic cells pulsed with islet antigen induce long-term reduction in T-cell autoreactivity in type 1 diabetes patients.
    Nikolic, T. et al. (2022) Front. Immunol. 13: 1054968. | Read article

  • Study protocol: A multicentre, open-label, parallel-group, phase 2, randomised controlled trial of autologous macrophage therapy for liver cirrhosis (MATCH).
    Brennan, P. N. et al. (2021) BMJ Open 11: e053190. | Read article

  • Immunological responses to adjuvant vaccination with combined CD1c+ myeloid and plasmacytoid dendritic cells in stage III melanoma patients.
    Bloemendal, M., et al. (2021) Oncoimmunology 11: 2015113. | Read article

  • Safety and feasibility of intradermal injection with tolerogenic dendritic cells pulsed with proinsulin peptide-for type 1 diabetes.
    Nikolic, T. et al. (2020) Lancet Diabetes Endocrinol. 8: 470–472. | Read article

  • Autologous dendritic cells pulsed with allogeneic tumor cell lysate in mesothelioma: From mouse to human.
    Aerts, J.G. et al. (2018) Clin. Cancer Res. 24: 766–776. | Read article

  • A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients.
    Inoges, S., Tejada, S. et al. (2017) J. Transl. Med. 15: 104. | Read article

  • Development, functional characterization and validation of methodology for GMP-compliant manufacture of phagocytic macrophages: A novel cellular therapeutic for liver cirrhosis.
    Fraser, A.R. et al. (2017) Cytotherapy 17: 30592–30593. | Read article

  • Generation of donor-specific Tr1 cells to be used after kidney transplantation and definition of the timing of their in vivo infusion in the presence of immunosuppression.
    Mfarrej, B. et al. (2017) J. Transl. Med. 15: 40. | Read article

  • Clinical testing of a dendritic cell targeted therapeutic vaccine in patients with chronic hepatitis C virus infection.
    Zabaleta, A. et al. (2015) Mol. Ther. Methods Clin. Dev. 2: 15006. | Read article

  • Dendritic cell vaccination in glioblastoma after fluorescence-guided resection.
    Valle, R.D. et al. (2012) World J. Clin. Oncol. 3: 142–149. | Read article

  • An optimized method for manufacturing a clinical scale dendritic cell-based vaccine for the treatment of glioblastoma.
    Nava, S. et al. (2012) PLoS One 12: e52301. | Read article

  • Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients.
    Alfaro, C. et al. (2011) J. Immunol. 187: 6130–42. | Read article

Summary table of clinical studies using CliniMACS Instruments

ReferenceCellular productCliniMACS SystemIndicationType of antigen
Berneman, Z.N. et al. (2025)Inflammatory Mo-DCsCliniMACS CD14 SystemSolid tumorsWT-1 mRNA electroporation
Brennan, P. N. et al. (2025)MacrophagesCliniMACS Prodigy LP-14 System
Liver cirrhosis–
Bol, K.F. et al. (2024)CD1c+ and CD304+ cellsCliniMACS LP-BDC SystemMelanomaMAGE-A3 and NY-ESO-1 (PepTivator Peptide Pools), gp100, Tyrosinase, MAGE-C2
van 't Land, F.R. et al. (2024)Inflammatory Mo-DCsCliniMACS CD14 SystemResected pancreatic cancerallogeneic mesothelioma tumor cell lysate
Tijtgat, J. et al. (2024)CD1c+ and CD141+ cellsCliniMACS LP-BDC SystemRefractory advanced melanoma–
Vounckx, M. et al. (2024)CD1c+ and CD141+ cellsCliniMACS LP-BDC SystemSolid tumors–
Aerts, J.G. et al. (2024)Inflammatory Mo-DCsCliniMACS CD14 SystemPleural mesothelioma
allogeneic tumour lysate
Nikolic, T. et al. (2022)Tolerogenic Mo-DCsCliniMACS CD14 SystemType 1 diabetesproinsulin peptide C19-A3
Schwarze J.K. et al. (2022)CD1c+ and/or CD141+ cellsCliniMACS CD1c+ System and CliniMACS LP-BDC SystemRefractory advanced melanoma–
Lau, S.P. et al. (2022)Inflammatory Mo-DCsCliniMACS CD14 SystemPancreatic cancerAllogeneic tumour cell line lysate
Bloemendal, M. et al. (2021)CD1c+ and CD304+ DCsCliniMACS LP-BDC SystemMelanomaMAGE-A3 and NY-ESO-1 (PepTivator Peptide Pools),Gp100, Tyrosinase, MAGE-C2
Nikolic, T. et al. (2020)Tolerogenic Mo-DCsCliniMACS CD14 SystemType 1 diabetesProinsulin peptide C19-A3
Schwarze, J. K. et al. (2020)CD1c+ DCs
CliniMACS CD1c SystemVarious solid tumors–
Sarivalasis, A. et al. (2019)Inflammatory Mo-DCsCliniMACS Prodigy LP-14 SystemOvarian cancerPersonalized peptide pools or tumor lysate
Westdorp, H. et al. (2019)CD1c+ DC and CD304+ DCsCliniMACS LP-BDC SystemProstate cancerNY-ESO-1, MAGE-C2, and MUC1 (PepTivator Peptide Pools)
Aerts, J.G. et al. (2018)Inflammatory Mo-DCsCliniMACS CD14 SystemMesotheliomaAllogeneic tumor cell line lysate
Fraser, A.R. et al. (2017)Regulatory macrophagesCliniMACS Prodigy LP-14 SystemLiver cirrhosis–
Anguille, S. et al. (2017)Inflammatory Mo-DCsCliniMACS CD14 SystemAcute myeloid leukemiaWT-1 mRNA electroporation
Inogés, S. Tejada, S. (2017)Inflammatory Mo-DCsCliniMACS CD14 SystemGlioblastomaTumor lysate
De Haar, C. et al. (2017)Cord blood DCsCliniMACS CD34 SystemAcute myeloid leukemiaWT-1 mRNA electroporation and WT1 peptides
Bell, G.M. et al. (2017)Tolerogenic Mo-DCsCliniMACS CD14 SystemRheumatoid and inflammatory arthritisAutologous synovial fluid
Schreibelt, G. et al. (2015)CD1c+ DCsCliniMACS CD1c SystemMelanomagp100 peptides
Prue, R. L. et al. (2015)CD1c+ DCsCliniMACS CD1c SystemProstate cancerProstate cancer associated peptides (PSA, PAP)
Zabaleta, A. et al. (2015)Inflammatory Mo-DCsCliniMACS CD14 SystemChronic hepatitis C virus infectionRecombinant adenovirus encoding HCV NS3 protein (AdNS3) fuse to CD40L ectodomain
Van Craenenbroeck, A. H. et al. (2015)Inflammatory Mo-DCsCliniMACS CD14 SystemCytomegalovirus infectionpp65 mRNA electroporation
Nava, S. et al. (2012)Inflammatory Mo-DCsCliniMACS CD14 SystemGlioblastomaTumor lysate
Iwami, K. et al. (2012)Inflammatory Mo-DCsCliniMACS CD14 SystemMalignant gliomaIL-13Rα2-derived peptides
Diez Valle, R. et al. (2012)Inflammatory Mo-DCsCliniMACS CD14 SystemGlioblastomaTumor lysate
Palma, M. et al. (2011)Inflammatory Mo-DCsCliniMACS CD14 SystemChronic lymphocytic leukemiaApoptotic B cells
Alfaro, C. et al. (2011)Inflammatory Mo-DCsCliniMACS CD14 SystemVarious metastatic solid tumorsTumor lysate
Bornhäuser, M. et al. (2011)Inflammatory Mo-DCs for T cellsCliniMACS CD14 SystemChronic myeloid leukemiaHuman leukocyte Ag-restricted peptides (from PR1, WT1, and/or BCR-ABL)
Muthuswamy, R. et al. (2010)Inflammatory Mo-DCsCliniMACS CD14 SystemMelanoma–
Van Tendeloo, V. et al. (2010)Inflammatory Mo-DCsCliniMACS CD14 SystemAcute myeloid leukemiaWT-1 mRNA electroporation
Van Driessche, A. et al. (2009)Inflammatory Mo-DCsCliniMACS CD14 SystemAcute myeloid leukemiaWT-1 mRNA electroporation
Di Nicola, M. et al. (2009)Inflammatory Mo-DCsCliniMACS CD14 SystemB cell lymphomaTumor specific IgH sequences
Adamson, L. et al. (2009)Inflammatory Mo-DCsCliniMACS CD14 SystemChronic lymphocytic leukemiaApoptotic B cells
Schwaab, T. et al. (2009)Inflammatory Mo-DCsCliniMACS CD14 SystemMetastatic renal cell carcinomaTumor lysate
Palma, M. et al. (2008)Inflammatory Mo-DCsCliniMACS CD14 SystemChronic lymphocytic leukemiaApoptotic B cells
Curti, A. et al. (2007)Inflammatory Mo-DCsCliniMACS CD14 SystemMultiple myelomaTumor specific IgH sequences
Fuessel, S. et al. (2006)Inflammatory Mo-DCsCliniMACS CD14 SystemProstate cancerProstate cancer associated peptides (prostein, survivin, PSMA, PSA, trp-p8)
Babatz, J. et al. (2006)Inflammatory Mo-DCsCliniMACS CD14 SystemColorectal cancer, lung cancerCarcinoembryonic antigen-derived altered peptide
Mazzolini, G. et al. (2005)Inflammatory Mo-DCsCliniMACS CD14 SystemMetastatic gastrointestinal carcinoma–
Höltl, L. et al. (2005)Inflammatory Mo-DCsCliniMACS CD14 SystemRenal cell carcinomaTumor lysate

Attention

The medical device and therapy related information on this website is intended for access by healthcare professionals only and their request.

By clicking "Accept" you are confirming that you are a healthcare professional and have read and agreed to the information above. If you are not a healthcare professional, please

click here

to be redirected to www.miltenyibiotec.com.